About this Journal Submit a Manuscript Table of Contents
Gastroenterology Research and Practice
Volume 2012 (2012), Article ID 317580, 7 pages
http://dx.doi.org/10.1155/2012/317580
Clinical Study

Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2

1Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto 1-7-1, Nagasaki 852-8501, Japan
2Department of Gastroenterology and Hepatology, Sasebo City General Hospital, Hirase-machi 9-3, Sasebo 857-8511, Japan
3Department of Gastroenterology and Hepatology, Nagasaki Municipal Hospital, Shinchi-machi 6-39, Nagasaki 850-8555, Japan
4Department of Gastroenterology and Hepatology, Japanese Red Cross Nagasaki Genbaku Hospital, Mori-machi 3-15, Nagasaki 852-8511, Japan
5Department of Gastroenterology and Hepatology, Oita Prefectural Hospital, Bunyo 467, Oita 870-8511, Japan
6Digestive Organ Center, Japan Labour and Welfare Organization, Nagasaki Labour Welfare Hospital, Setogoe 2-12-5, Sasebo 857-0134, Japan
7Department of Gastroenterology and Hepatology, Sasebo Chuo Hospital, Yamato-machi 15, Sasebo 857-1195, Japan
8Department of Internal Medicine, Goto Central Hospital, Nagasaki Prefectural, Yoshikugichou 205, Goto 853-0031, Japan
9Department of Internal Medicine, National Hospital Organization Saga National Hospital, Hinode 1-20-1, Saga 849-8577, Japan
10Department of Internal Medicine, Kouseikai Hospital, Hayama1-3-12, Nagasaki 852-8053, Japan
11Department of Gastroenterology and Hepatology, Medical Inc. Kosei-kai Nijigaoka Hospital, Nijigaoka-machi 1-1, Nagasaki 852-8055, Japan
12Department of Internal Medicine, Caritas Clinic, Nishiizuru-machi 65-7, Nagasaki 851-2322, Japan
13Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Kubara 2-1001-1, Omura, Nagasaki 856-8562, Japan

Received 16 May 2012; Accepted 24 September 2012

Academic Editor: Edoardo Giovanni Giannini

Copyright © 2012 Naota Taura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Barrera, M. Bruguera, M. G. Ercilla et al., “Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C,” Hepatology, vol. 21, no. 3, pp. 639–644, 1995. View at Scopus
  2. F. Penin, J. Dubuisson, F. A. Rey, D. Moradpour, and J. M. Pawlotsky, “Structural biology of hepatitis C virus,” Hepatology, vol. 39, no. 1, pp. 5–19, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. S. J. Hadziyannis, H. Sette, T. R. Morgan et al., “Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose,” Annals of Internal Medicine, vol. 140, no. 5, pp. 346–355, 2004. View at Scopus
  4. M. P. Manns, J. G. McHutchison, S. C. Gordon et al., “Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial,” The Lancet, vol. 358, no. 9286, pp. 958–965, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Ye, “Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus,” PLoS Pathogens, vol. 3, no. 8, p. e108, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Ogawa, T. Hishiki, Y. Shimizu et al., “Hepatitis C virus utilizes lipid droplet for production of infectious virus,” Proceedings of the Japan Academy B, vol. 85, no. 7, pp. 217–228, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Negro and A. J. Sanyal, “Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data,” Liver International, vol. 29, supplement 2, pp. 26–37, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Gopal, T. C. Johnson, S. Gopal et al., “Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment,” Hepatology, vol. 44, no. 2, pp. 335–340, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Economou, H. Milionis, S. Filis et al., “Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C,” Journal of Gastroenterology and Hepatology, vol. 23, no. 4, pp. 586–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Ramcharran, A. S. Wahed, H. S. Conjeevaram et al., “Associations between serum lipids and hepatitis C antiviral treatment efficacy,” Hepatology, vol. 52, no. 3, pp. 854–863, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Ferenci, M. W. Fried, M. L. Shiffman et al., “Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin,” Journal of Hepatology, vol. 43, no. 3, pp. 425–433, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Inoue, N. Hiramatsu, T. Oze et al., “Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses,” Journal of Viral Hepatitis, vol. 17, no. 5, pp. 336–344, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. V. J. Desmet, M. Gerber, J. H. Hoofnagle, M. Manns, and P. J. Scheuer, “Classification of chronic hepatitis: diagnosis, grading and staging,” Hepatology, vol. 19, no. 6, pp. 1513–1520, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Romero-Gómez, M. Del Mar Viloria, R. J. Andrade et al., “Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients,” Gastroenterology, vol. 128, no. 3, pp. 636–641, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Marotta, D. Hueppe, E. Zehnter, P. Kwo, and I. Jacobson, “Efficacy of chronic hepatitis C therapy in community-based trials,” Clinical Gastroenterology and Hepatology, vol. 7, no. 10, pp. 1028–1036, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Maekawa and N. Enomoto, “Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C,” Journal of Gastroenterology, vol. 44, no. 10, pp. 1009–1015, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. D. L. Thomas, C. L. Thio, M. P. Martin et al., “Genetic variation in IL28B and spontaneous clearance of hepatitis C virus,” Nature, vol. 461, no. 7265, pp. 798–801, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Y. Minuk, S. Weinstein, and K. D. Kaita, “Serum cholesterol and low-density lipoprotein cholesterol levels as predictors of response to interferon therapy for chronic hepatitis C,” Annals of Internal Medicine, vol. 132, no. 9, pp. 761–762, 2000. View at Scopus
  19. G. Testino and P. Borro, “Hepatitis C recurrence: influence of serum cholesterol levels and liver steatosis on antiviral therapy,” Hepatology, vol. 53, no. 4, pp. 1409–1410, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Villa, A. Karampatou, C. Camm et al., “Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C,” Gastroenterology, vol. 140, no. 3, pp. 818–829, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Haffner, “Rationale for new American Diabetes Association Guidelines: are national cholesterol education program goals adequate for the patient with diabetes mellitus?” American Journal of Cardiology, vol. 96, no. 4, pp. 33E–36E, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. C. D. Miller, L. S. Phillips, M. K. Tate et al., “Meeting American Diabetes Association guidelines in endocrinologist practice,” Diabetes Care, vol. 23, no. 4, pp. 444–448, 2000. View at Scopus
  23. C. Fabris, E. Federico, G. Soardo, E. Falleti, and M. Pirisi, “Blood lipids of patients with chronic hepatitis: differences related to viral etiology,” Clinica Chimica Acta, vol. 261, no. 2, pp. 159–165, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Monazahian, I. Böhme, S. Bonk et al., “Low density lipoprotein receptor as a candidate receptor for hepatitis C virus,” Journal of Medical Virology, vol. 57, no. 3, pp. 223–229, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. J. M. Petit, A. Minello, L. Duvillard et al., “Cell surface expression of LDL receptor in chronic hepatitis C: correlation with viral load,” American Journal of Physiology, vol. 293, no. 1, pp. E416–E420, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Molina, V. Castet, C. Fournier-Wirth et al., “The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus,” Journal of Hepatology, vol. 46, no. 3, pp. 411–419, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Ge, J. Fellay, A. J. Thompson et al., “Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance,” Nature, vol. 461, no. 7262, pp. 399–401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Suppiah, M. Moldovan, G. Ahlenstiel et al., “IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy,” Nature Genetics, vol. 41, no. 10, pp. 1100–1104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. J. H. Li, X. Q. Lao, H. L. Tillmann et al., “Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection,” Hepatology, vol. 51, no. 6, pp. 1904–1911, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Chayama, C. N. Hayes, K. Yoshioka et al., “Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C,” Hepatology Research, vol. 40, no. 12, pp. 1155–1167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Honda and Y. Matsuzaki, “Cholesterol and chronic hepatitis C virus infection,” Hepatology Research, vol. 41, no. 8, pp. 697–710, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Petta and A. Craxì, “Optimal therapy in hepatitis C virus genotypes 2 and 3 patients,” Liver International, vol. 31, supplement 1, pp. 36–44, 2011. View at Publisher · View at Google Scholar · View at Scopus